Eli Lilly is one of the most valuable pharmaceutical companies globally, with a market capitalization driven by breakthrough therapies in diabetes, obesity, and Alzheimer's disease, and a pipeline increasingly shaped by computational approaches to drug discovery. The company's engineering challenges include building AI/ML platforms for molecular simulation and target identification, developing large-scale data pipelines that integrate clinical trial data with real-world evidence, and modernizing the digital infrastructure supporting manufacturing and supply chain operations for biologics at unprecedented scale. Their technology organization spans computational chemistry, biostatistics platforms, commercial analytics, and the enterprise systems required to support a rapidly growing product portfolio. Lilly's hiring patterns reflect the pharmaceutical industry's accelerating investment in AI-driven drug discovery, with growing demand for ML engineers, data scientists, and platform engineers who can bridge computational biology and production-grade software systems.
| Location | Listings |
|---|